O f the newly diagnosed cases of breast cancer in Canada, 80% were in women over the age of 50 years, and about 28% were in women aged 70 years or older (Figure 1), 1 with little variation by pro vince. Regular screening for breast cancer with mammography, breast self -examinations and clinical breast examinations are widely recommended to reduce mortality due to breast cancer. Although controversy remains over precisely which screening services should be provided and to whom, these methods are frequently used in contemporary practice.
2-4Outcomes of screening for breast cancer such as tumour detection and mortality must be put into context of the harms and costs of falsepositive results, overdiagnosis and overtreatment. Consideration of benefits, harms and costs is complicated by variations in risk factors and in the types and stages of cancer.Any positive result from screening has emotional costs such as anxiety and worry for patients and their families, and financial costs to both the patient and the health care system as a result of additional and potentially unnecessary diagnostic tests. For women with positive results on screening tests, additional diagnostic tests will usually be recommended, such as further mammography, ultrasound and/or tissue sampling with core needle biopsy.This document updates the previous guidelines issued by the Canadian Task Force on Preventive Health Care (2001). 5,6 The absence of current Canadian recommendations, the recent controversy over the best way to screen for breast cancer among women at average risk of the disease, 7,8 the availability of new technologies such as magnetic resonance imaging (MRI) and a recent review of the evidence 9 were the basis for selecting this topic for an update by the revitalized Canadian Task Force on Preventive Health Care.Recommendations are presented for the use of mammography, MRI, breast self-examination and clinical breast examination to screen for breast cancer among women at average risk of disease (defined as those with no previous breast cancer, no history of breast cancer in a firstdegree relative, no known mutations in the BRCA1/BRCA2 genes or no previous exposure of the chest wall to radiation). Re commendations are provided separately for women aged 40-49, 50-69 and 70-74 years and are aimed at clinicians and policy-makers. The recommendations are intended to inform both organized and opportunistic screening.
Methods
The Canadian Task Force on Preventive HealthCare is an independent panel of clinicians and methodologists with expertise in prevention, primary care, literature synthesis, critical appraisal and the application of evidence to practice and policy. The task force makes recommendations about clinical manoeuvres aimed at primary and secondary prevention. (Please see www .canadiantaskforce .ca /members_eng.html for a list of current members of the task force.)Work on each recommendation is led by a workgroup of two to five members of the task force; a list of members of the workgroup for the current guidelines is availab...